JCCT 243 A
The main purpose of this study is to test an injectable, investigational medication which is being developed to lower the risk of getting COVID.
JCCT 243
The main purpose of this study is to test an injectable, investigational medication which is being developed to lower the risk of getting COVID.
JCCT 236
The purpose of this research is to test a new investigational vaccine, VAX-31. VAX-31 causes the body to make antibodies (germ fighters) in adults who previously received a pneumococcal vaccine, and potentially increases the amount of antibodies to the strains in common with the previous pneumococcal vaccine.
JCCT 241
This study will help find out how well the COVID-19 vaccine (BNT162b2) may help protect against COVID-19 in people aged 50-64 years of age who don’t have any serious medical issues that put them at higher risk of severe COVID-19. The study will compare the COVID-19 vaccine to a placebo.
JCCT 229
The purpose of this research is to test a new investigational vaccine VAX-31. We are doing this study to learn about the safety of VAX-31 and whether VAX-31 causes the body to make antibodies (germ‑fighting proteins in the blood).
JCCT 240
The purpose of this study is to evaluate the efficacy and safety of two Covid-19 vaccines, compared to a placebo in adults aged 50 to 64 years who do not have underlying conditions that put them at high risk for severe outcomes from Covid-19.
JCCT 239
The purpose of this study is to learn about the effects of cadisegliatin (also called “TTP399”) compared to placebo to find out if or how much cadisegliatin may reduce the episodes of low blood sugar (hypoglycemia) in T1DM, or lower HbA1c, and to see how people with T1DM feel and do when taking cadisegliatin (how the study drug is tolerated).
JCCT 235
This study will evaluate the safety and efficacy of tirzepatide for the treatment of participants with MASLD who are at increased risk of major adverse liver outcome (MALO) events (high-risk MASLD).
CRC 018
We are doing this study to learn more about a new drug called AZD7760 when it is given as an intravenous (IV; into the vein) infusion to healthy adults (Phase I) or adults with end‑stage kidney disease who are on hemodialysis with a central venous catheter (Phase IIa).
CRC 011
We are doing this study to learn more about the benefits and safety of treatment of an experimental drug called baxdrostat in combination with dapagliflozin for treating patients with CKD and high blood pressure. We also want to better understand CKD and the health problems that come with it.
